Newron H1 FY26 net loss widens to EUR 16.4 million; revenue drops 73.2% to EUR 3.2 million

• Newron posted H1 2026 revenue of EUR 3.19 million, down 73.2% from a year earlier.
• Net loss widened to EUR 16.37 million, swinging from a EUR 73,000 loss; R&D expenses more than doubled to EUR 14.55 million.
• Cash and other current financial assets rose to EUR 32.89 million at June 30, 2026, up 13.9% from Dec. 31, 2025.
• ENIGMA-TRS 1 screening completed in September; target enrollment of at least 600 patients is expected around mid-October, with topline 12-week data in Q1 2027.
• Following a Type A FDA meeting, Newron expects U.S. enrollment in ENIGMA-TRS 2 to resume in the near future, while enrollment continues outside the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.